Presenilin-2 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-Presenilin2
In stock
- SKU
- REC-Presenilin2
Target Overview
Presenilin-2 (PSEN2; UniProt P49810) is the catalytic subunit of the γ-secretase complex, a multi-subunit intramembrane aspartyl protease responsible for the regulated cleavage of type I transmembrane substrates including amyloid precursor protein (APP) and Notch family receptors. The full-length human PSEN2 open reading frame encodes a 448-amino-acid polytopic membrane protein that undergoes endoproteolytic processing to yield an N-terminal fragment (NTF) and a C-terminal fragment (CTF), both of which are retained in the active γ-secretase holocomplex. This recombinant is expressed in HEK293 cells, an expression system well suited to the production of mammalian integral membrane proteins requiring co-translational glycosylation and membrane-associated folding chaperones. HEK293-derived material closely recapitulates the post-translational modifications and processing events observed in endogenous human PSEN2, making it appropriate for biochemical and cell-free assay contexts where native conformation is relevant. In the laboratory, this reagent supports several research workflows. It serves as a positive control antigen in Western blot and immunoprecipitation experiments, and researchers using it for antibody validation can pair it with the matched Triple Point Biologics anti-Presenilin-2 antibody (RP-Presenilin2). It is additionally used as a defined component in reconstituted γ-secretase activity assays, enabling measurement of APP substrate cleavage and Aβ peptide generation in vitro. The recombinant protein is also employed in inhibitor and modulator binding studies — including dose-response characterisation of small-molecule γ-secretase inhibitors (GSIs) and modulators (GSMs) — as well as in surface plasmon resonance (SPR) and pull-down experiments designed to map PSEN2 protein-protein interactions within the γ-secretase complex.
Background
Applications
- Reconstituted γ-secretase activity assay measuring APP substrate cleavage and Aβ peptide generation in vitro
- Inhibitor IC50 determination for γ-secretase inhibitors (GSIs) using fluorogenic or ELISA-based Aβ readouts
- γ-Secretase modulator (GSM) dose-response characterisation monitoring Aβ42/Aβ40 ratio shifts
- Antibody validation positive control in Western blot — pairs with matched Triple Point Biologics anti-Presenilin-2 antibody (RP-Presenilin2)
- Immunoprecipitation and co-IP assays to map PSEN2 interactions within the γ-secretase holocomplex (nicastrin, APH-1, PEN-2)
- Surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding kinetics with candidate small-molecule or peptide ligands
- Calcium channel functional assays examining passive ER-to-cytosol calcium flux mediated by PSEN2 holoprotein
- Substrate selectivity profiling comparing APP vs. Notch cleavage efficiency in reconstituted cell-free systems
References
- Lindemann L et al. Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease. Front Pharmacol. 2026. doi: 10.3389/fphar.2026.1783414. PMID: 42292846.
- Ricci S et al. ZL006 Treatment Reduces Inflammation, Oxidative Stress, and Brain Aβ(1-42) Accumulation and Rescues the Loss of PSD95 Synaptic Marker in Familial Alzheimer's Disease-Associated psen1-Deficient Zebrafish Model. Int J Mol Sci. 2026. doi: 10.3390/ijms27114992. PMID: 42278518.
- Totuk O. CHMP2B p.Ala30Ser Variant in Biomarker-Confirmed Early-Onset Alzheimer Disease: A Potential Endolysosomal Disease Modifier. Alzheimer Dis Assoc Disord. 2026. doi: 10.1097/WAD.0000000000000737. PMID: 42246690.
- Heshetha M et al. Integrated in silico docking, ADMET, and network pharmacology evaluation of Althaea officinalis L. phytocompounds targeting Park2 for the management of Parkinson's disease. Inflammopharmacology. 2026. doi: 10.1007/s10787-026-02296-1. PMID: 42295684.
- Tran VL. Early-onset dilated cardiomyopathy associated with a novel CRYAB variant complicated by non-sustained ventricular tachycardia: a case report. Eur Heart J Case Rep. 2026. doi: 10.1093/ehjcr/ytag299. PMID: 42170542.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Multi-pass transmembrane; ER + Golgi; γ-secretase complex |
Frequently Asked Questions
What molecular weight does recombinant Presenilin-2 run at on SDS-PAGE and Western blot?
Full-length human PSEN2 has a predicted molecular weight of ~50 kDa, but endoproteolytic processing generates an N-terminal fragment (NTF, ~28–30 kDa) and a C-terminal fragment (CTF, ~20–24 kDa). Under denaturing SDS-PAGE conditions, you will typically observe both processed fragments rather than a dominant full-length band, reflecting the near-complete autoproteolysis that occurs co-translationally in HEK293 cells. Confirm band identity with our matched antibody RP-Presenilin2, which is validated to recognize both NTF and CTF on Western blot.
Is this recombinant Presenilin-2 the full-length protein or a processed fragment?
The recombinant is expressed from the full-length 448-amino-acid human PSEN2 open reading frame (UniProt P49810) in HEK293 cells. However, PSEN2 undergoes obligate endoproteolytic autocleavage during biogenesis, so the final product contains the NTF and CTF held in non-covalent association — the same configuration found in the endogenous active γ-secretase holocomplex. This makes it biochemically representative of the catalytically competent form, not an artificially truncated construct.
What substrates does recombinant Presenilin-2 cleave in a cell-free γ-secretase activity assay?
As the catalytic aspartyl protease subunit of γ-secretase, PSEN2 processes type I transmembrane substrates including the C99 and C83 fragments of amyloid precursor protein (APP) and Notch intracellular domain (NICD) precursors. For in vitro activity assays, a commonly used substrate is a fluorogenic APP-derived peptide (e.g., MLSF-based FRET peptides) or recombinant APP-C99 fragment. Proteolytic activity produces Aβ peptides (Aβ40/Aβ42 for APP). Validate cleavage products by Aβ ELISA or mass spectrometry alongside appropriate γ-secretase inhibitor controls such as DAPT or L-685,458.
What buffer conditions are recommended for Presenilin-2 recombinant activity assays?
The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — conditions compatible with most cell-free γ-secretase assay formats. For activity assays, dilute into assay buffer containing 50 mM sodium acetate or HEPES pH 7.0–7.4, supplemented with 0.1–0.25% CHAPSO or DDM detergent to maintain membrane protein solubility. Avoid strong ionic detergents (SDS, Triton X-100 above 0.1%) and reducing agents above 1 mM DTT, as these disrupt the NTF–CTF heterodimer association critical for catalytic activity.
What is a recommended starting concentration for Presenilin-2 in an in vitro γ-secretase cleavage assay?
A practical starting point is 50–200 nM recombinant PSEN2 (as part of a reconstituted or semi-purified γ-secretase complex) with substrate concentrations in the 1–10 µM range, assaying for 2–4 hours at 37°C. Because PSEN2 functions within the multi-subunit complex, activity in isolation from nicastrin, APH-1, and PEN-2 may be reduced; consider supplementing with native membrane fractions or co-expressing complex partners. Titrate enzyme from 25–500 nM to establish linearity before running inhibitor IC50 experiments.
How do I use recombinant Presenilin-2 as a positive control for Western blot with the RP-Presenilin2 antibody?
Load 50–200 ng of recombinant PSEN2 per lane on a 12–15% SDS-PAGE gel. After transfer, probe with RP-Presenilin2 (/anti-presenilin-2-rabbit-polyclonal-antibody) at a 1:500–1:2,000 dilution in 5% non-fat milk/TBST. Expect bands at ~28–30 kDa (NTF) and ~20–24 kDa (CTF). This recombinant and antibody originate from the same production pipeline, so band identity is guaranteed to match, making this combination a reliable positive control for antibody validation experiments or when establishing PSEN2 detection in novel tissue lysates.
How much recombinant Presenilin-2 should I load as a Western blot positive control alongside cell lysate?
For a clean, non-overloaded positive control lane, 100 ng is a reliable starting point. At this quantity, both the NTF (~28–30 kDa) and CTF (~20–24 kDa) bands are detectable with RP-Presenilin2 without saturating the signal. If your cell lysate lanes contain very low PSEN2 expression (e.g., non-neuronal lines), you may drop to 50 ng to keep the positive control lane intensity comparable. Run the recombinant in a dedicated lane separate from lysate to avoid cross-contamination and confirm expected mobility against your molecular weight ladder.
How should I store and handle recombinant Presenilin-2 to maintain activity and avoid degradation?
Store at −20°C in single-use aliquots immediately upon receipt. The supplied buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) provides cryoprotection, but repeated freeze-thaw cycles progressively disrupt the NTF–CTF heterodimer and reduce activity — avoid more than one freeze-thaw per aliquot. On ice, working aliquots are stable for up to 8 hours. For dilutions below ~10 nM, add 0.1% BSA (protease-free) as a carrier to minimize adsorptive losses on tube walls. Purity is >90% by SDS-PAGE; endotoxin is confirmed <0.1 EU/µg by LAL assay.
Validation imagery coming soon
Western blot validation figures for REC-Presenilin2 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.